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Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with considerable evidence 
suggesting an initiation of disease in the entorhinal cortex and hippocampus and spreading 
thereafter to the rest of the brain. In this study, we combine genetics and imaging data obtained 
from the Alzheimer's Disease Neuroimaging Initiative and the AddNeuroMed study. To identify 
genetic susceptibility loci for AD, we conducted a genome-wide study of atrophy in regions 
associated with neurodegeneration in this condition. We identified one single-nucleotide 
polymorphism (SNP) with a disease-specific effect associated with entorhinal cortical volume in 
an intron of the ZNF292 gene (rs1925690; P-value = 2.6× 10−8; corrected P-value for equivalent 
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number of independent quantitative traits = 7.7 × 10−8) and an intergenic SNP, flanking the 
ARPP-21 gene, with an overall effect on entorhinal cortical thickness (rs11129640; P-value = 5.6 
× 10−8; corrected P-value = 1.7 × 10−7). Gene-wide scoring also highlighted PICALM as the most 
significant gene associated with entorhinal cortical thickness (P-value = 6.7 × 10−6).
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Introduction
The US NIH Alzheimer's Disease Neuroimaging Initiative (ADNI)1 and the European Union 
FP6-funded AddNeuroMed study2 have complementary goals. ADNI is a 5-year public–
private partnership investigating the effectiveness of integrating neuroimaging, genetic/
biological markers, as well as clinical and neuropsychological assessments in measuring the 
progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The 
main aim of the AddNeuroMed study, also a private–public partnership and a pilot for the 
European FP6 Innovative Medicines Initiative, is to find biomarkers for AD, in particular for 
early diagnosis of the disease. Both projects have acquired similar data, and in this study, we 
integrate neuroimaging and genetic data obtained from the two projects to identify novel 
susceptibility loci for AD.
Research to identify genetic factors that predispose to AD recently resulted in the 
publication of two large-scale genome-wide association studies (GWASs). Harold et al.3 
analyzed >16000 individuals in a two-stage case–control analysis, identifying, in addition to 
APOE, two loci that were significantly associated with AD (namely CLU and PICALM). 
Another large-scale study by Lambert et al.4 also found association with the CLU locus and 
additionally with the CR1 locus. These findings have elucidated some of the genes that are 
causally implicated in predisposition to AD. However, the diseased case versus normal 
control design of these GWASs and the studies that preceded them have an inherent 
confound in that a proportion of the apparently normal control population will already 
harbor disease because of the long clinically silent prodromal phase. One way to address this 
confound is the use of endophenotypes of disease—that is, markers of pathology in vivo that 
can be used to separate diseased from normal individuals more accurately than can be 
achieved by clinical assessment alone, and hence have the potential for greater power than 
studies using the standard AD/normal case–control design. One approach to endophenotypes 
as a marker of disease in genetic studies is the use of imaging measures in a quantitative trait 
(QT) analysis.
This imaging-genetics approach has been undertaken by a number of previous studies in 
AD. Potkin et al.5 identified a number of loci potentially associated with hippocampal 
atrophy in a subset of the ADNI cohort (AD and control samples). Shen et al.6 combined 
whole-genome genotyping data with 142 measures of gray matter density, volume and 
cortical thickness in the full ADNI cohort. However, they focused on the main effects of 
each single-nucleotide polymorphism (SNP) and did not investigate disease-specific effects.
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In this study, we integrate magnetic resonance imaging (MRI) measures and genome-wide 
common variation data in a combined data set of 939 subjects (236 AD, 424 MCI and 279 
controls) from the AddNeuroMed2 study and the ADNI;1 both these public–private 
partnerships having common objectives and, critically for this analysis, common genetics 
and imaging protocols.7,8 We had two aims: (1) to carry out a GWAS of AD-related brain 
regions and (2) to investigate the influence of AD-related genes and loci reported by recent 
large-scale GWASs for AD,3,4 specifically, the CLU, PICALM and CR1 loci. We focus on 
brain regions that are unequivocally affected by AD-related neurodegeneration, namely the 
hippocampus and entorhinal cortex, and also on the related measures whole-brain volume 
(WBV) and total ventricular volume (VV). We use these MRI-derived measures as QTs to 
determine disease-specific common variants associated with neural atrophy in patients with 
AD.
Materials and methods
Samples
A total of 281 subjects were selected from the AddNeuroMed study, a prospective, 
longitudinal multicenter study, to discover biomarkers for AD.2 Data were collected from six 
medical centers across Europe: University of Kuopio (Finland), University of Perugia 
(Italy), Aristotle University of Thessaloniki (Greece), King's College London (United 
Kingdom), Medical University of Lodz (Poland) and University of Toulouse (France). 
Informed consent was obtained for all subjects, and protocols and procedures were approved 
by the relevant institutional review board at each data acquisition site. Neuropsychological 
tests were conducted at baseline. None of the MCI and AD subjects had other neurological 
or psychiatric disease, significant unstable systemic illness or organ failure and alcohol or 
substance misuse. AD diagnosis was made using the NINCDS-ADRDA (National Institute 
of Neurological and Communicative Disease and Stroke and Alzheimer's disease) criteria 
for probable AD.9 At baseline, all MCI subjects fulfilled the diagnostic criteria for amnestic 
MCI.10,11 A total of 281 patients were genotyped (94 AD, 96 MCI and 91 controls) and 
underwent MRI.
Data for 818 ADNI subjects were downloaded from the ADNI database (http://
www.loni.ucla.edu/ADNI), including baseline 1.5-T MRI scans, Illumina genotyping data 
(Illumina, San Diego, CA, USA), demographic and neuropsychological information, APOE 
genotype and baseline diagnosis information (see Supplementary Methods for details).
Genotyping
Genotyping for all samples was performed using the Illumina HumanHap610-Quad 
BeadChips, which contain 620 901 markers. ADNI genotyping was conducted as described 
previously. 6 AddNeuroMed genotyping was performed by the CNG (Centre National de 
Génotypage CNG, France) (see Supplementary Methods for details). The APOE genotype 
was obtained separately using standard methods.
AddNeuroMed and ADNI genotyping data were merged, and any ambiguous or uncalled 
SNPs were removed using PLINK.12 SNPs with call rates < 98% or minor allele frequencies 
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<5% were excluded. The Hardy–Weinberg equilibrium was assessed in control samples and 
SNPs with Hardy–Weinberg equilibrium <10−5 were excluded. A total of 488 911 SNPs 
passed quality control protocols. Individual samples with SNP call rates <98% were 
excluded. Gender and relatedness tests were conducted in PLINK. Individuals with 
incongruous or ambiguous SNP genders compared with clinical genders were excluded. In 
cases in which pairs of samples were related (PI-HAT > 0.1875), one of the samples was 
removed at random. Ethnicity information was available for all participants. To restrict the 
analysis data set to Caucasian samples, so as to avoid confounding effects due to differing 
allele frequencies in other populations, the samples were merged with the Hapmap phase 3 
populations,13 and a population stratification analysis was conducted using Eigenstrat.14 
Samples classified as non-European were excluded based on ethnicity information and 
Eigenstrat analysis (AddNeuroMed n =0, ADNI n =64). Overall, 1004 samples passed these 
quality control filters (AddNeuroMed n = 278, ADNI n =726). The genotyping rate in these 
samples was 0.998.
Imaging
Data acquisition—Data acquisition for AddNeuroMed15 and ADNI8 took place using 
1.5-T MR systems using a common protocol, which included a high-resolution sagittal 
three-dimensional T1-weighted MPRAGE volume (voxel size 1.1 × 1.1 × 1.2 mm3) and 
axial proton density/T2-weighted fast spin echo images. Full brain and skull coverage was 
required for both of the latter data sets, and a detailed quality control was carried out on all 
MR images using the AddNeuroMed QC framework.15 All MR images received a clinical 
read by a radiologist to exclude any subjects with non-AD-related pathologies.
AddNeuroMed and ADNI image analysis—A highly automated structural MRI image 
processing pipeline developed by Fischl and Dale16 and Fischl et al.17,18 and producing both 
regional cortical thickness measures and regional volume measures was used for data 
analysis. Cortical reconstruction and volumetric segmentation included removal of the 
nonbrain tissue using a hybrid watershed/surface deformation procedure, automated 
Talairach transformation, segmentation of the subcortical white matter and deep gray matter 
volumetric structures (including the hippocampus, amygdala, caudate, putamen, ventricles) 
intensity normalization, tessellation of the gray matter–white matter boundary, automated 
topology correction and surface deformation following intensity gradients to optimally place 
the gray/white and gray/cerebrospinal fluid borders at the location where the greatest shift in 
intensity defines the transition to the other tissue class. Surface inflation was followed by 
registration to a spherical atlas, which used individual cortical folding patterns to match 
cortical geometry across subjects and parcellation of the cerebral cortex into units based on 
gyral and sulcal structures. All volumes were normalized by the subject's intracranial 
volume (ICV).
Regional cortical thickness was measured from 34 areas, and regional cortical volume was 
measured bilaterally from 24 areas. In total, images obtained from 1097 AddNeuroMed and 
ADNI samples passed imaging quality control and produced normalized WBVs. Measures 
for total hippocampal volume (HPV), VV, total entorhinal cortical volume (ERV) and mean 
(of left and right) entorhinal cortical thickness were extracted for 1070 samples.
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QT analysis
The four normalized (by ICV) volumetric measures WBV, HPV, VV, ERV and the cortical 
thickness measure mean (of left and right) entorhinal cortical thickness (ERT) were used as 
QTs in separate regression analyses. ERT was not normalized by ICV. Including ICV as a 
covariate in the ERT analysis produces very similar results (r of regression coefficients = 
0.999), and ICV is not significant in any of the regressions. The numbers of samples that 
passed both imaging and genotyping quality control protocols and for which there were 
complete relevant phenotypic and demographic data were 963 (WBV) and 939 (HPV, VV, 
ERV and ERT).
QT analyses were implemented using the linear model function (--linear) in PLINK, which 
allows covariates to be included in the linear model.12 Each QT was regressed on the 
number of minor alleles of the 478 081 autosomal SNPs passing quality control criteria, 
assuming an additive allele effect. A number of different linear models were analyzed:
1. The additive allele effect was ascertained in an initial model, including age, 
gender, APOE ε4 allele dosage and disease status as covariates. Disease status 
was coded as a continuous variable in the model (controls=0, MCI=1, AD=2) to 
reflect the nonindependent nature of the three diagnosis states. The genomic 
inflation factor (based on median χ2 of the additive term in the model) was 
calculated to investigate potential population stratification effects in the analysis. 
The genomic inflation factors for WBV, HPV and VV for this model were > 
1.05, indicating potential population effects. The ERV and ERT analyses had 
genomic inflation factors of 1.01.
2. To allow for population effects, Eigenstrat14 was run using the 1004 samples that 
passed quality control. Seven significant eigenvectors were detected using 
Tracy–Widom statistics. Model 1 was re-run for WBV, HPV and VV, including 
the seven significant eigenvalues for each sample. The genomic inflation factors 
for WBV, HPV and VV for this model were 1.00, 1.00 and 1.01, respectively.
3. To detect SNP effects that may differ according to disease status, an interaction 
term for disease status and the additive allele effect was included in the third 
model. For ERV and ERT, the covariates age, gender, APOE ε4 allele dosage and 
disease status were included in the model. For WBV, HPV and VV, significant 
eigenvalues were further added.
To allow for multiple testing of five QTs (namely WBV, HPV, VV, ERV and ERT) that are 
correlated (Supplementary Table 1), we applied Matrix Spectral Decomposition (see http://
gump.qimr.edu.au/general/daleN/matSpD/), based on the study by Nyholt,19 to QTs, which 
results in an effective number of independent variables of 3, using VeffLi.
Gene analysis
We performed linkage disequilibrium (LD)-based SNP grouping in PLINK12 on the results 
of our entorhinal cortical thickness analysis using the --clump command with default 
settings. We also performed a set-based analysis in PLINK, using SNPs ±100 kb of 
PICALM and ±750 kb of ARPP-21 (because of the intergenic location of the significant 
Furney et al. Page 5
Mol Psychiatry. Author manuscript; available in PMC 2018 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
associated SNP) as sets of genes and permuting 10000 times. This analysis was 
implemented by PLINK as follows (from http://pngu.mgh.harvard.edu/∼purcell/plink/
anal.shtml#set): For the gene set, for each SNP, determine which other SNPs are in LD, 
above a certain threshold R (0.5). Perform standard single SNP QT analysis. For the set, 
select up to N ‘independent’ SNPs (as defined before) with P-values below P (0.05). The 
best SNP is selected first; subsequent SNPs are selected in order of decreasing statistical 
significance, after removing SNPs in LD with previously selected SNPs. From these subsets 
of SNPs, the statistic for each set is calculated as the mean of these single SNP statistics. 
Permute the data set 10 000 times, keeping LD between SNPs constant (that is, permute 
trait). The empirical P-value for set (EMP1) is the number of times the permuted set statistic 
exceeds the original one for the set.
Finally, we used a novel method for calculating gene-based P-values from GWA results (see 
Supplementary Methods for details). We restricted our analysis to ∼20 000 protein-coding 
genes annotated in Ensembl v56 and mapped them to SNPs if the SNP was within 20 kb of 
the annotated coordinates.
Imputation
To further investigate the evidence of association at the PICALM, ARRP-21 and ZNF292 
loci, we imputed SNPs in the region ±500 kb of PICALM and ZNF292 and in ±750 kb of 
the ARRP-21 locus with minor allele frequency >0.01 and imputation quality scores ≥0.99 
in the CEU Hapmap phase 2 population20 and the 1000 Genomes project21 using Beagle22 
and IMPUTE,23 respectively, and applied the QT analysis.
Results
QT analysis
Previous work has shown brain atrophy in patients with AD to be most pronounced in 
hippocampal and entorhinal cortical regions, as well as in WBV in MRI studies.7,24–26 The 
decreases in these areas and the corresponding increase in ventricular volume in the 
participants in this study are congruent with previous findings (Supplementary Figure 1). 
Although there are significant correlations between the neuroimaging traits that we 
measured (Supplementary Table 1), we aimed to identify structure-specific variants 
associated with disease and markers of general neurodegeneration (Table 1).
In brief, 1118 subjects were genotyped using the Illumina 610K Beadchip, and standard 
sample and SNP quality control measures were implemented (see the ‘Materials and 
methods’ section). Samples classified as non-European were excluded based on ethnicity 
information and principal components analysis.14 Measures of entorhinal cortical thickness 
and volume, hippocampal volume, together with total brain and ventricular volumes were 
derived using automated regional analysis as described previously7 (see the ‘Materials and 
methods’ section). We implemented models with and without the SNP by disease 
interaction, the latter model allowing us to investigate the main SNP effect in addition to 
disease-associated SNP effects identified by the interaction term in the former model. 
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Quantile–quantile plots and Manhattan plots of the results are shown in Supplementary 
Figures 2–5.
This analysis identified one SNP (Table 2a) with a disease-specific effect associated with 
entorhinal cortical volume at the genome-wide significance threshold of P<5 × 10−8 in an 
intron of the ZNF292 gene (rs1925690; P-value = 2.6 × 10−8; corrected P-value for 
equivalent number of independent QTs = 7.7 × 10−8; Figure 1a) and an intergenic SNP, 
flanking the ARPP-21 gene, with a main effect in entorhinal cortical thickness close to this 
threshold (rs11129640; P-value = 5.6 × 10−8; corrected P-value = 1.7 × 10−7; Figure 1b). 
Neither of these variants has been previously associated with neurodegeneration, nor is 
either significantly associated with AD in the recent GWASs.3,4 ZNF292 encodes a putative 
zinc-finger protein of unknown function. The disease-specific effect of this SNP is shown in 
Supplementary Figure 6. The ARPP-21 gene encodes a neuronal phosphoprotein enriched in 
regions of the brain receiving dopaminergic innervation.27 In all, 29 SNPs representing 21 
different loci have main effects with P-values < 10−5 (Supplementary Table 2), and 24 SNPs 
representing 17 loci have disease-associated effects with P-values < 10−5 (Supplementary 
Table 3). Imputation of variants proximal to the ARPP-21 and ZNF292 loci (see the 
‘Materials and methods’ section) identified a number of additional variants at P-values 
<10−4 proximal to rs11129640 (Supplementary Figure 7), but none in the case of the 
ZNF292 rs1925690 variant, Supplementary Figure 8). LD-based SNP grouping was carried 
out for the ARPP-21 and ZNF292 loci; however, this analysis did not reveal any further 
SNPs. A set-based analysis of the ARPP-21 locus using SNPs ± 750 kb of ARPP-21 as a set 
of genes and permuting 10 000 times, resulted in an empirical P-value < 10−4 and revealed 5 
SNPs at P<0.05 passing the LD threshold (see the ‘Materials and methods’ section).
In light of recent large-scale GWASs for AD,3,4 we then sought to identify any corroboratory 
evidence in our analyses for the genome-wide significant variants at the CLU, PICALM and 
CR1 loci from these studies. The rs11136000 SNP in clusterin identified by Harold et al.3 
and Lambert et al.4 is not significantly associated with any of the imaging QTs, nor is the 
rs6701713 variant in CR1 identified by Lambert et al.4 The PICALM-associated SNP 
rs3851179 identified by Harold et al.,3 the minor allele of which they found to have an odds 
ratio of 0.86, is associated with an increase in entorhinal cortical thickness (uncorrected P< 
0.05; Table 2b) in our main effect analysis. We then performed LD-based SNP grouping in 
PLINK12 on the results of our entorhinal cortical thickness analysis. This highlighted the 
intronic PICALM SNP rs642949 (uncorrected P-value = 9.6 × 10−5) as being in LD with 
two further SNPs with P-values < 0.001 (Figure 2a). We also performed a set-based analysis 
in PLINK, using SNPs ± 100 kb of PICALM as a gene set and permuting 10 000 times. Of 
the 11 SNPs significant at P<0.05, 5 variants were independently significant (based on an r2 
threshold of 0.5), resulting in an empirical P-value = 0.0034. To investigate the evidence of 
association at the PICALM locus further, we imputed SNPs with minor allele frequency 
>0.01 and imputation quality scores ≥0.99 in the CEU Hapmap phase 2 population20 and the 
1000 Genomes project21 using Beagle22 and IMPUTE,23 respectively, and applied the QT 
analysis. Although none of the imputed SNPs reaches suggestive significance, there are a 
further eleven Hapmap phase 2 SNPs and five 1000 genome SNPs at P-values <10−3 
(Figures 2b and c).
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As there seemed to be multiple nominally positive SNPs in the region, we used a novel 
method for calculating gene-based P-values from GWA results (see the ‘Materials and 
methods’ section). We restricted our analysis to ∼20 000 protein-coding genes annotated in 
Ensembl v56 and mapped them to genotyped SNPs within 20 kb of the annotated 
coordinates. We calculated gene-wide P-values using a modified Fisher's method to combine 
P-values from correlated tests and applied a local false discovery rate. This method 
identified PICALM as the most significant gene in the main entorhinal cortical thickness 
analysis (P-value = 6.7 × 10−6; false discovery rate = 0.039; Table 3). The ARPP-21 gene 
was not significant in this analysis (false discovery rate = 1), most likely because of the most 
significant SNP being located outside our threshold of 20 kb. The method was also applied 
to the disease-specific entorhinal cortical volume analysis, revealing ZNF292 as the thirty-
fifth most significant gene (false discovery rate = 0.25).
Discussion
We present a genome-wide QT study for brain atrophy as an endophenotype for AD 
pathology of >900 participants from the ADNI and AddNeuroMed projects. To our 
knowledge, this is the largest study integrating imaging measures and genetics in AD. We 
selected brain regions known to be affected by AD (such as the hippocampus, entorhinal 
cortex and whole brain) and in which atrophy has been highlighted by previous MRI studies.
7,24–26,28
 MRI scans were processed to produce volumetric measures of these regions of 
interest and also entorhinal cortical thicknesses. Genotyping data (∼478K SNPs) were 
integrated with the imaging traits in QT analyses.
We used this imaging QTL approach first for all subjects and then with disease status as an 
interaction effect because we reasoned that this study design would have greater power to 
detect disease susceptibility loci than a case versus control design. In the latter, more usual 
approach, the presence of clinically silent cases in the control group and susceptible but 
unaffected people presents a substantial confound. Using a measure of active disease as an 
endophenotype might help to overcome this problem.
Our design also includes a large number of MCI subjects, adding to the power of the study. 
However, many MCI subjects will not progress to AD and a recent meta-analysis by 
Mitchell et al.29 showed an annual conversion rate of 8.1% and a cumulative proportion of 
33.6% for MCI conversion to dementia, although it is noted that some studies show higher 
proportions of conversion, and in all studies, some MCI subjects fail to progress only 
because of death. Although the findings we report in this study will require replication, we 
note that despite the relatively small sample size compared with GWASs (1000 versus > 10 
000) it is striking that we observe main SNP and disease-specific effects that reach nominal 
genome-wide significance (Table 2a).
The most significant SNP (P = 6.54 × 10−8; main ERT analysis) we identify is proximal to 
the ARPP-21 gene, a regulator of calmodulin signaling, that is involved in the cellular cAMP 
signaling pathway, particularly in striatal medium spiny neurons.30 Calmodulin signaling 
has been widely implicated in AD pathogenesis (see the study by O'Day and Myre31 for a 
review). In addition to identifying common variants that are associated with disease 
Furney et al. Page 8
Mol Psychiatry. Author manuscript; available in PMC 2018 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
susceptibility, we included an interaction term between disease status and the additive SNP 
effect in the analysis. Implementing this model with our QTs, we identified 24 SNPs 
correlated with the brain regions at P-values <10−5 and one SNP <10−6 (Supplementary 
Table 3). The most significant SNP (ERV; P-value = 3.45 × 10∼8) is in an intron in the 
ZNF292 gene, which codes for a zinc-finger protein expressed in the brain.32 Our disease-
specific analysis highlights the association between the minor allele of this SNP (rs1925690) 
and increased entorhinal cortical volume (Supplementary Figure 6) in AD subjects, whereas 
the converse is evident in control individuals.
Our analysis suggests further evidence for the PICALM locus in neurodegeneration. Using a 
genecentric approach, we identify a number of SNPs contributing to a locus association with 
entorhinal cortical thickness (Figure 2). The PICALM variant identified by Harold et al.3 
and other more significant variants in our study are associated with less atrophy in the 
entorhinal cortex, suggesting a protective effect. The PICALM protein is involved in 
clathrin-mediated endocytosis, inhibition of which has recently been shown to decrease 
levels of amyloid-β in brain interstitial fluid in mice.33
We have focused on a small number of regions known to be affected in AD and have 
conducted main and disease-specific effects for all SNPs in both the ADNI and the 
AddNeuroMed cohorts. Our study design was different from the previously published study 
of the ADNI cohort by Shen et al.6 in that we restricted our analysis to regions previously 
strongly implicated in the etiopathology of AD and reprocessed all neuroimages. This meant 
that we tested different phenotypes to those of Shen et al. in our combined ADNI and 
AddNeuroMed cohort. These differences and the design of the study by Shen et al. do not 
allow a direct comparison of the results, and we would consider that we have conducted an 
independent analysis of the data.
Our data provide further evidence of a causal role for PICALM in AD, demonstrate the 
power of endophenotype-genotype association studies and further identify two genes, 
namely ARPP-21 and ZNF292, as putative risk factors for this devastating and common 
neurodegenerative disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(a) Manhattan plot of SNP effect P-values from the disease-specific entorhinal cortical 
volume analysis. (b) Manhattan plot of SNP effect P-values from the main entorhinal 
cortical thickness analysis. SNP, single-nucleotide polymorphism.
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Figure 2. 
SNP effect P-values from the main entorhinal cortical thickness analysis in the region 
surrounding PICALM for (a) original results (b) HapMap phase 2 SNPs and (c) 1000 
Genomes Project SNPs. rs3851179 (in blue) is the SNP identified in the Harold et al.3 AD 
GWAS. Figure 2 was adapted from SNAP34 output. AD, Alzheimer's disease; GWAS, 
genome-wide association study; SNP, single-nucleotide polymorphism. The color 
reproduction of this figure is available on the html full text version of the manuscript.
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